MetaVia Initiates Phase 1 Trial for DA-1726, Targeting Obesity and Metabolic Health

MetaVia Inc. (Nasdaq: MTVA), a biotechnology company specializing in cardiometabolic diseases, announced the dosing of the first patient in Part 3 of its Phase 1 clinical trial for DA-1726. This dual GLP-1 and glucagon receptor agonist targets obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). The trial features two 16-week cohorts focusing on one-step and two-step dose-escalation strategies to enhance tolerability. The trial aims to enroll 40 adult subjects, 20 per cohort, to evaluate various safety and efficacy endpoints. Early results from an earlier 48 mg dosage demonstrated approximately 9% weight loss along with improved glycemic control, highlighting the compound's potential over existing therapies. As stated by Hyung Heon Kim, CEO of MetaVia, the goal is to optimize therapeutic doses while maintaining safety. The company aims to report further data in the fourth quarter of 2026, which may provide significant insights on DA-1726's efficacy in treating obesity more effectively than current options.,MetaVia has launched the first patient dosing in a higher-dose Phase 1 clinical trial for DA-1726, a novel dual agonist that targets both GLP-1 and glucagon receptors. This innovative approach is designed specifically for the treatment of obesity, with the study set to rigorously evaluate various factors including safety and tolerability, as well as pharmacokinetics and pharmacodynamics in subjects who are obese. The dual mechanism of DA-1726 is expected to provide significant advantages in weight loss and enhancing metabolic health. The GLP-1 receptor agonist is known to promote insulin secretion while glucagon contributes to increasing energy expenditure. This combination could potentially lead to more effective obesity management strategies. MetaVia expresses enthusiasm about the future prospects of DA-1726 as they continue to explore and research advancements in obesity treatment.